Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

West Pharmaceutical Services, Inc. applies value-added services to the process of bringing new drug therapies and healthcare products to global markets. The Company"s technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services.
Website: westpharma.com



Growth: Pretty weak revenue growth rate 7.8%, there is acceleration compared to average historical growth rates 1.3%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -26.7%

Profitability: LTM EBITDA margin is positive, +38.6%. On average the margin is decreasing unsteadily. Gross margin is normal, +36.5%. In the last quarter the company beat the estimated EPS, +18.6%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.21 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.4%. Free cash flow yield 1.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 26.8% higher than minimum and 41.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.5x by EV / Sales multiple , the company can be 39.6% overvalued

Key Financials (Download financials)

Ticker: WST
Share price, USD:  (0.0%)241.4
year average price 243.41  


year start price 321.55 2025-02-08

max close price 324.13 2025-02-10

min close price 190.39 2025-04-08

current price 241.40 2026-02-07
Common stocks: 74 400 000

Dividend Yield:  0.4%
FCF Yield LTM: 1.3%
EV / LTM EBITDA: 15.1x
EV / EBITDA annualized: 20.9x
Last revenue growth (y/y):  +7.8%
Last growth of EBITDA (y/y):  +5.5%
Historical revenue growth:  +1.3%
Historical growth of EBITDA:  +8.9%
EV / Sales: 5.8x
Margin (EBITDA LTM / Revenue): 38.6%
Fundamental value created in LTM:
Market Cap ($m): 17 960
Net Debt ($m): -331
EV (Enterprise Value): 17 629
Price to Book: 5.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05seekingalpha.com

West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript

2026-01-30zacks.com

Here's Why West Pharmaceutical (WST) Is a Great 'Buy the Bottom' Stock Now

2026-01-29prnewswire.com

West to Host Fourth-Quarter and Full-Year 2025 Conference Call

2026-01-23zacks.com

WST Launches Synchrony S1 Prefillable Syringe at Pharmapack

2026-01-22zacks.com

All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy

2026-01-21zacks.com

After Plunging 9.7% in 4 Weeks, Here's Why the Trend Might Reverse for West Pharmaceutical (WST)

2026-01-14seekingalpha.com

West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-14zacks.com

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

2026-01-13zacks.com

Wall Street Analysts See a 26.42% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?

2025-12-12prnewswire.com

West to Participate in Upcoming Investor Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol WST WST WST WST WST WST WST WST WST WST WST WST WST WST
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770
fillingDate 2025-10-23 2025-07-24 2024-10-24 2024-07-25 2024-04-25 2023-10-26 2023-07-27 2023-04-27 2022-10-27
acceptedDate 2025-10-23 16:14:52 2025-07-24 16:22:04 2025-02-18 16:44:56 2024-10-24 16:21:38 2024-07-25 16:10:57 2024-04-25 16:24:24 2024-02-20 16:44:29 2023-10-26 16:26:21 2023-07-27 16:16:35 2023-04-27 16:10:11 2023-02-21 16:18:23 2022-10-27 16:21:38 2022-02-22 16:22:31 2021-02-23 16:49:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 804M 766M 2 893M 747M 702M 695M 2 951M 747M 754M 717M 2 886M 687M 2 831M 2 147M
costOfRevenue 511M 493M 1 891M 482M 471M 465M 1 818M 459M 462M 445M 1 747M 419M 1 657M 1 379M
grossProfit 294M 273M 1 002M 265M 231M 230M 1 133M 288M 291M 271M 1 139M 268M 1 173M 768M
grossProfitRatio 0.365 0.357 0.354 0.329 0.331 0.386 0.387 0.379 0.39
researchAndDevelopmentExpenses 17M 19M 69M 16M 18M 18M 68M 16M 17M 17M 59M 14M 53M 47M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 103M 96M 339M 84M 83M 87M 353M 89M 88M 86M 317M 66M 362M 302M
otherExpenses 0 0 0 0 3M -3M 0 -2M -4M 13M 0 0 0 0
operatingExpenses 120M 115M 408M 99M 101M 107M 422M 105M 105M 116M 375M 80M 415M 349M
costAndExpenses 631M 608M 2 298M 581M 571M 573M 2 240M 565M 567M 561M 2 122M 499M 2 072M 1 728M
interestIncome 5M 4M 20M 5M 4M 6M 28M -9M 5M 5M 5M 2M 1 000 000 1M
interestExpense 100 000 100 000 3M 700 000 2M 2M 9M 3M 3M 2M 8M 2M 9M 9M
depreciationAndAmortization 43M 41M 155M 40M 39M 36M 137M 36M 34M 32M 121M 34M 122M 109M
ebitda 217M 199M 744M 205M 168M 158M 844M 219M 221M 187M 808M 173M 880M 519M
ebitdaratio 0.27 0.259 0.275 0.242 0.228 0.292 0.293 0.261 0.252
operatingIncome 174M 158M 595M 161M 131M 123M 711M 177M 183M 155M 764M 139M 759M 419M
operatingIncomeRatio 0.216 0.206 0.216 0.186 0.177 0.237 0.242 0.217 0.203
totalOtherIncomeExpensesNet 300 000 4M 6M 3M 7M 5M 5M -2M -4M 3M -63M -3M 10M -300 000
incomeBeforeTax 174M 162M 600M 165M 129M 127M 716M 187M 185M 158M 701M 136M 769M 419M
incomeBeforeTaxRatio 0.216 0.211 0.22 0.183 0.183 0.25 0.245 0.22 0.198
incomeTaxExpense 34M 30M 108M 32M 22M 16M 122M 29M 35M 24M 115M 20M 107M 73M
netIncome 140M 132M 493M 136M 111M 115M 593M 161M 155M 140M 586M 121M 662M 346M
netIncomeRatio 0.174 0.172 0.182 0.159 0.166 0.216 0.206 0.195 0.176
eps 1.94 1.82 6.75 1.87 1.52 1.57 7.99 2.17 2.08 1.88 7.88 1.62 8.9 4.68
epsdiluted 1.92 1.82 1.85 1.51 1.55 2.14 2.06 1.85 1.59
weightedAverageShsOut 72M 72M 73M 73M 73M 74M 74M 74M 74M 75M 74M 74M 74M 74M
weightedAverageShsOutDil 73M 73M 74M 73M 74M 74M 75M 75M 75M 76M 76M 76M 76M 76M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 17M 19M -3M -8M -7M
ebit 588M 707M 688M 757M 410M
nonOperatingIncomeExcludingInterest 6M 4M 76M 1M 9M
netIncomeFromContinuingOperations 493M 593M 586M 662M 346M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 493M 593M 586M 662M 346M
epsDiluted 6.69 7.88 7.73 8.67 4.57

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol WST WST WST WST WST WST WST WST WST WST WST WST WST WST
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770
fillingDate 2025-10-23 2025-07-24 2024-10-24 2024-07-25 2024-04-25 2023-10-26 2023-07-27 2023-04-27 2022-10-27
acceptedDate 2025-10-23 16:14:52 2025-07-24 16:22:04 2025-02-18 16:44:56 2024-10-24 16:21:38 2024-07-25 16:10:57 2024-04-25 16:24:24 2024-02-20 16:44:29 2023-10-26 16:26:21 2023-07-27 16:16:35 2023-04-27 16:10:11 2023-02-21 16:18:23 2022-10-27 16:21:38 2022-02-22 16:22:31 2021-02-23 16:49:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 629M 510M 485M 491M 446M 602M 854M 899M 796M 886M 894M 729M 763M 616M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 629M 510M 485M 491M 446M 602M 854M 899M 796M 886M 894M 729M 763M 616M
netReceivables 653M 582M 553M 524M 502M 524M 512M 519M 534M 513M 507M 485M 489M 385M
inventory 438M 421M 377M 401M 419M 430M 435M 432M 449M 447M 415M 413M 378M 321M
otherCurrentAssets 104M 168M 124M 134M 116M 137M 136M 123M 94M 91M 103M 106M 112M 52M
totalCurrentAssets 1 823M 1 681M 1 538M 1 551M 1 483M 1 693M 1 936M 1 972M 1 874M 1 937M 1 920M 1 734M 1 742M 1 374M
propertyPlantEquipmentNet 3 331M 1 826M 1 686M 1 711M 1 635M 1 545M 1 513M 1 408M 1 361M 1 316M 1 263M 1 156M 1 127M 1 012M
goodwill 111M 111M 106M 109M 107M 108M 109M 107M 108M 108M 107M 104M 110M 111M
intangibleAssets 9M 10M 11M 12M 13M 14M 15M 16M 17M 18M 18M 18M 23M 31M
goodwillAndIntangibleAssets 120M 121M 117M 121M 120M 122M 124M 123M 125M 126M 126M 122M 133M 142M
longTermInvestments 221M 225M 202M 218M 198M 203M 210M 195M 203M 209M 205M 189M 208M 215M
taxAssets 28M 30M 26M 38M 34M 21M 26M 17M 67M 99M 66M 63M 49M 16M
otherNonCurrentAssets -1 417M 71M 74M 37M 19M 19M 21M 39M 40M 37M 38M 54M 56M 36M
totalNonCurrentAssets 2 283M 2 272M 2 105M 2 125M 2 006M 1 909M 1 893M 1 782M 1 795M 1 786M 1 697M 1 583M 1 572M 1 420M
otherAssets 0 0 -100 000 0 0 0 0 0 0 0 0 0 0 0
totalAssets 4 106M 3 953M 3 643M 3 675M 3 489M 3 602M 3 830M 3 755M 3 670M 3 724M 3 617M 3 317M 3 314M 2 794M
accountPayables 256M 239M 239M 224M 212M 240M 242M 220M 218M 234M 215M 189M 232M 213M
shortTermDebt 23M 21M 19M 20M 154M 151M 134M 72M 18M 18M 2M 16M 44M 2M
taxPayables 33M 29M 50M 33M 17M 17M 31M 15M 27M 59M 39M 30M 39M 41M
deferredRevenue 0 0 50M 0 17M 17M 42M 15M 27M 0 57M 0 49M 51M
otherCurrentLiabilities 323M 316M 101M 239M 251M 240M 54M 227M 249M 283M 54M 252M 45M 50M
totalCurrentLiabilities 635M 605M 550M 517M 634M 648M 672M 534M 512M 535M 519M 457M 594M 503M
longTermDebt 280M 282M 203M 285M 160M 155M 73M 235M 293M 296M 207M 284M 209M 253M
deferredRevenueNonCurrent 0 0 0 2M 87M 48M 0 2M 48M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 23M 23M 21M 9M 14M 13M 13M 17M 15M 15M 14M 17M 5M 10M
otherNonCurrentLiabilities 116M 114M 104M 112M 105M 58M 107M 100M 55M 102M 99M 185M 108M 112M
totalNonCurrentLiabilities 419M 419M 411M 407M 279M 273M 277M 353M 411M 413M 413M 389M 384M 436M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 77M 101M 84M 102M 108M 100M 102M 100M 104M 106M 109M 91M 72M 71M
totalLiabilities 1 054M 1 024M 961M 923M 913M 922M 949M 887M 923M 947M 932M 846M 978M 939M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 19M 19M 19M 19M 19M 19M 19M 19M 19M 19M 19M 19M 19M 19M
retainedEarnings 4 262M 4 139M 3 957M 3 857M 3 721M 3 624M 3 523M 3 416M 3 255M 3 114M 2 988M 2 913M 2 457M 1 847M
accumulatedOtherComprehensiveIncomeLoss -102M -89M -258M -136M -217M -192M -144M -223M -184M -168M -183M -309M -160M -111M
othertotalStockholdersEquity -1 127M -1 140M -987M -946M -770M -344M -343M -188M -153M
totalStockholdersEquity 3 052M 2 929M 2 682M 2 752M 2 577M 2 681M 2 881M 2 868M 2 747M 2 776M 2 685M 2 471M 2 335M 1 855M
totalEquity 3 052M 2 929M 2 682M 2 752M 2 577M 2 681M 2 881M 2 868M 2 747M 2 776M 2 685M 2 471M 2 335M 1 855M
totalLiabilitiesAndStockholdersEquity 4 106M 3 953M 3 675M 3 489M 3 602M 3 755M 3 670M 3 724M 3 317M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4 106M 3 953M 3 643M 3 675M 3 489M 3 602M 3 830M 3 755M 3 670M 3 724M 3 617M 3 317M 3 314M 2 794M
totalInvestments 221M 225M 202M 218M 198M 203M 210M 195M 203M 209M 205M 189M 208M 215M
totalDebt 303M 303M 305M 305M 314M 307M 309M 307M 311M 314M 318M 300M 325M 326M
netDebt -326M -206M -179M -186M -132M -295M -545M -592M -485M -572M -576M -429M -437M -290M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 553M 512M 507M 489M 385M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 271M 288M 273M 285M 267M
otherPayables 32M 46M 57M 53M 54M
accruedExpenses 111M 136M 117M 162M 123M
capitalLeaseObligationsCurrent 0 18M 16M 9M 10M
capitalLeaseObligationsNonCurrent 84M 85M 93M 63M 60M
treasuryStock -1 057M -638M -371M -230M -168M
additionalPaidInCapital 22M 120M 232M 249M 267M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol WST WST WST WST WST WST WST WST WST WST WST WST WST WST
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770 105 770
fillingDate 2025-10-23 2025-07-24 2024-10-24 2024-07-25 2024-04-25 2023-10-26 2023-07-27 2023-04-27 2022-10-27
acceptedDate 2025-10-23 16:14:52 2025-07-24 16:22:04 2025-02-18 16:44:56 2024-10-24 16:21:38 2024-07-25 16:10:57 2024-04-25 16:24:24 2024-02-20 16:44:29 2023-10-26 16:26:21 2023-07-27 16:16:35 2023-04-27 16:10:11 2023-02-21 16:18:23 2022-10-27 16:21:38 2022-02-22 16:22:31 2021-02-23 16:49:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 140M 132M 493M 136M 111M 115M 593M 161M 155M 140M 586M 121M 662M 346M
depreciationAndAmortization 43M 41M 155M 40M 39M 36M 137M 36M 34M 32M 121M 30M 122M 109M
deferredIncomeTax 0 0 0 0 0 0 38M -192M 4M 0 -31M 0 -43M -6M
stockBasedCompensation 8M 7M 19M 5M 4M 5M 23M 6M 8M 9M 24M 6M 38M 34M
changeInWorkingCapital 2M -100 000 3M -100 000 14M -35M -20M 25M -25M -47M -15M -32M -194M -10M
accountsReceivables 0 0 -59M 0 0 0 4M 0 0 0 -36M 0 -124M -47M
inventory 0 0 42M 0 0 0 -14M 0 0 0 -50M 0 -87M -74M
accountsPayables 0 0 3M 0 0 0 4M 0 0 0 -3M 0 17M 37M
otherWorkingCapital 2M -100 000 17M -100 000 14M -35M -15M 25M 0 0 73M 0 -600 000 73M
otherNonCashItems 4M -3M -16M -1M 79M -4M 5M 194M -6M 5M 36M 44M -900 000 -700 000
netCashProvidedByOperatingActivities 197M 177M 653M 180M 165M 118M 777M 230M 169M 138M 724M 169M 584M 473M
investmentsInPropertyPlantAndEquipment -63M -75M -377M -81M -100M -91M -362M -96M -75M -82M -285M -58M -253M -174M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 -2M 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -800 000 -1 000 000 0 100 000 -7M 0 -59M
netCashUsedForInvestingActivites -63M -75M -82M -101M -91M -96M -82M -82M -59M
debtRepayment -300 000 -300 000 -4M -23M -600 000 -600 000 -500 000 -600 000 -43M
commonStockIssued 4M 0 0 0 17M 20M 0 0 0
commonStockRepurchased 0 -500 000 -567M -52M -187M -272M -451M -28M -174M -72M -222M -28M -152M -121M
dividendsPaid -15M -15M -15M -15M -15M -14M -14M -14M -14M
otherFinancingActivites -100 000 1 000 000 6M 7M -100 000 -300 000 12M 15M 8M
netCashUsedProvidedByFinancingActivities -12M -15M -64M -218M -271M -22M -177M -71M -75M
effectOfForexChangesOnCash -4M 19M -21M 11M -1M -9M 11M -10M -300 000 7M -11M -24M -16M 21M
netChangeInCash 119M 106M -369M 45M -156M -252M -40M -566M -90M -8M 132M 11M 147M 176M
cashAtEndOfPeriod 629M 510M 485M 491M 446M 602M 854M 230M 796M 886M 894M 729M 763M 616M
cashAtBeginningOfPeriod 510M 404M 854M 446M 602M 854M 894M 796M 886M 894M 763M 719M 616M 439M
operatingCashFlow 197M 177M 653M 180M 165M 118M 777M 230M 169M 138M 724M 169M 584M 473M
capitalExpenditure -63M -75M -377M -81M -100M -91M -362M -96M -75M -82M -285M -58M -253M -174M
freeCashFlow 134M 102M 276M 99M 65M 28M 415M 134M 94M 56M 439M 111M 331M 298M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -2M -7M -4M 3M -5M
netCashProvidedByInvestingActivities -379M -369M -288M -253M -180M
netDebtIssuance -28M -2M -44M -2M -2M
longTermNetDebtIssuance -28M -2M -44M -2M -2M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -567M -451M -222M -152M -121M
netCommonStockIssuance -567M -451M -222M -152M -121M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -59M -57M -54M -51M -48M
commonDividendsPaid -59M -57M -54M -51M -48M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 31M 51M 27M 37M 35M
netCashProvidedByFinancingActivities -623M -460M -294M -168M -137M
incomeTaxesPaid 71M 91M 110M 172M 48M
interestPaid 500 000 6M 7M 8M 8M

Earning call transcript

2025 q3
2025-10-23 ET (fiscal 2025 q3)
2025 q2
2025-07-24 ET (fiscal 2025 q2)
2025 q1
2025-04-24 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-24 ET (fiscal 2024 q3)
2024 q2
2024-07-25 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-10-23 20:14 ET
West Pharmaceutical Services reported for 2025 q3
SEC form 8
2025-10-23 11:15 ET
West Pharmaceutical Services published news for 2025 q3
SEC form 8
2025-10-23 11:15 ET
West Pharmaceutical Services published news for 2025 q3
SEC form 8
2025-10-23 11:15 ET
West Pharmaceutical Services published news for 2025 q3
SEC form 10
2025-07-24 20:22 ET
West Pharmaceutical Services reported for 2025 q2
SEC form 8
2025-07-24 11:17 ET
West Pharmaceutical Services published news for 2025 q2
SEC form 8
2025-07-24 11:17 ET
West Pharmaceutical Services published news for 2025 q2
SEC form 8
2025-07-24 11:17 ET
West Pharmaceutical Services published news for 2025 q2
SEC form 8
2025-05-08 20:46 ET
West Pharmaceutical Services published news for 2025 q1
SEC form 8
2025-05-08 20:46 ET
West Pharmaceutical Services published news for 2025 q1
SEC form 10
2025-04-24 20:19 ET
West Pharmaceutical Services reported for 2025 q1
SEC form 8
2025-04-24 11:47 ET
West Pharmaceutical Services published news for 2025 q1
SEC form 8
2025-04-24 11:47 ET
West Pharmaceutical Services published news for 2025 q1
SEC form 8
2025-04-24 11:47 ET
West Pharmaceutical Services published news for 2025 q1
SEC form 10
2025-04-24 00:00 ET
West Pharmaceutical Services published news for 2025 q1
SEC form 10
2025-02-18 21:44 ET
West Pharmaceutical Services published news for 2024 q4
SEC form 10
2025-02-18 00:00 ET
West Pharmaceutical Services published news for 2024 q4
SEC form 8
2025-02-13 08:00 ET
West Pharmaceutical Services published news for 2024 q4
SEC form 8
2025-02-13 08:00 ET
West Pharmaceutical Services reported for 2024 q4
SEC form 8
2025-02-13 08:00 ET
West Pharmaceutical Services published news for 2024 q4
SEC form 10
2024-10-24 16:21 ET
West Pharmaceutical Services reported for 2024 q3
SEC form 8
2024-10-24 07:50 ET
West Pharmaceutical Services published news for 2024 q3
SEC form 8
2024-10-24 07:50 ET
West Pharmaceutical Services published news for 2024 q3
SEC form 8
2024-10-24 07:50 ET
West Pharmaceutical Services published news for 2024 q3
SEC form 10
2024-10-24 00:00 ET
West Pharmaceutical Services published news for 2024 q3
SEC form 10
2024-07-25 16:10 ET
West Pharmaceutical Services published news for 2024 q2
SEC form 8
2024-07-25 08:05 ET
West Pharmaceutical Services published news for 2024 q2
SEC form 8
2024-07-25 08:05 ET
West Pharmaceutical Services reported for 2024 q2
SEC form 8
2024-07-25 08:05 ET
West Pharmaceutical Services published news for 2024 q2
SEC form 10
2024-07-25 00:00 ET
West Pharmaceutical Services published news for 2024 q2
SEC form 10
2024-04-25 16:24 ET
West Pharmaceutical Services published news for 2024 q1
SEC form 8
2024-04-25 07:42 ET
West Pharmaceutical Services published news for 2024 q1
SEC form 8
2024-04-25 07:42 ET
West Pharmaceutical Services reported for 2024 q1
SEC form 8
2024-04-25 07:42 ET
West Pharmaceutical Services published news for 2024 q1
SEC form 10
2024-04-25 00:00 ET
West Pharmaceutical Services published news for 2024 q1
SEC form 10
2024-02-20 00:00 ET
West Pharmaceutical Services published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
West Pharmaceutical Services published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
West Pharmaceutical Services reported for 2023 q4
SEC form 8
2024-02-15 00:00 ET
West Pharmaceutical Services published news for 2023 q4
SEC form 10
2023-10-26 16:26 ET
West Pharmaceutical Services published news for 2023 q3
SEC form 8
2023-10-26 07:41 ET
West Pharmaceutical Services reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
West Pharmaceutical Services published news for 2023 q3
SEC form 10
2023-07-27 16:16 ET
West Pharmaceutical Services published news for 2023 q2
SEC form 6
2023-07-27 07:46 ET
West Pharmaceutical Services reported for 2023 q2
SEC form 10
2023-07-27 00:00 ET
West Pharmaceutical Services published news for 2023 q2
SEC form 8
2023-07-27 00:00 ET
West Pharmaceutical Services published news for 2023 q2
SEC form 6
2023-06-28 16:07 ET
West Pharmaceutical Services published news for 2023 q1
SEC form 6
2023-06-28 16:06 ET
West Pharmaceutical Services published news for 2023 q1
SEC form 10
2023-04-27 00:00 ET
West Pharmaceutical Services published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
West Pharmaceutical Services published news for 2023 q1
SEC form 10
2023-02-21 16:18 ET
West Pharmaceutical Services reported for 2022 q4
SEC form 10
2023-02-21 00:00 ET
West Pharmaceutical Services reported for 2022 q4
SEC form 6
2023-02-16 07:40 ET
West Pharmaceutical Services published news for 2022 q4
SEC form 8
2023-02-16 00:00 ET
West Pharmaceutical Services reported for 2022 q4
SEC form 10
2022-10-27 16:21 ET
West Pharmaceutical Services reported for 2022 q3
SEC form 6
2022-10-27 07:50 ET
West Pharmaceutical Services published news for 2022 q3
SEC form 10
2022-10-27 00:00 ET
West Pharmaceutical Services reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
West Pharmaceutical Services reported for 2022 q3
SEC form 10
2022-07-28 16:04 ET
West Pharmaceutical Services reported for 2022 q2
SEC form 6
2022-07-28 07:37 ET
West Pharmaceutical Services published news for 2022 q2
SEC form 10
2022-07-28 00:00 ET
West Pharmaceutical Services reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
West Pharmaceutical Services reported for 2022 q2
SEC form 6
2022-07-27 07:37 ET
West Pharmaceutical Services published news for 2022 q2
SEC form 6
2022-06-23 16:17 ET
West Pharmaceutical Services published news for 2022 q1
SEC form 6
2022-06-23 16:16 ET
West Pharmaceutical Services published news for 2022 q1
SEC form 6
2022-05-26 16:07 ET
West Pharmaceutical Services published news for 2022 q1
SEC form 6
2022-05-12 16:32 ET
West Pharmaceutical Services published news for 2022 q1
SEC form 10
2022-04-28 16:04 ET
West Pharmaceutical Services reported for 2022 q1
SEC form 6
2022-04-28 07:52 ET
West Pharmaceutical Services published news for 2022 q1
SEC form 10
2022-04-28 00:00 ET
West Pharmaceutical Services reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
West Pharmaceutical Services reported for 2022 q1
SEC form 6
2022-04-14 09:00 ET
West Pharmaceutical Services published news for 2022 q1
SEC form 6
2022-04-01 16:11 ET
West Pharmaceutical Services published news for 2022 q1
SEC form 6
2022-02-28 17:01 ET
West Pharmaceutical Services published news for 2021 q4
SEC form 10
2022-02-22 16:22 ET
West Pharmaceutical Services published news for 2021 q4
SEC form 10
2022-02-22 00:00 ET
West Pharmaceutical Services published news for 2021 q4
SEC form 6
2022-02-17 07:51 ET
West Pharmaceutical Services published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
West Pharmaceutical Services published news for 2021 q4
SEC form 10
2021-10-28 16:01 ET
West Pharmaceutical Services published news for 2021 q3
SEC form 6
2021-10-28 08:17 ET
West Pharmaceutical Services published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
West Pharmaceutical Services published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
West Pharmaceutical Services published news for 2021 q3
SEC form 6
2021-08-24 08:40 ET
West Pharmaceutical Services published news for 2021 q2
SEC form 6
2021-08-23 16:40 ET
West Pharmaceutical Services published news for 2021 q2
SEC form 10
2021-07-30 07:58 ET
West Pharmaceutical Services published news for 2021 q2
SEC form 10
2021-07-30 00:00 ET
West Pharmaceutical Services published news for 2021 q2
SEC form 6
2021-07-29 08:07 ET
West Pharmaceutical Services published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
West Pharmaceutical Services published news for 2021 q2
SEC form 6
2021-06-24 16:46 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 6
2021-06-24 16:45 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 6
2021-05-06 17:01 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 10
2021-04-30 16:03 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 6
2021-04-29 20:34 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 6
2021-04-29 07:20 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
West Pharmaceutical Services published news for 2021 q1
SEC form 6
2021-03-24 07:00 ET
West Pharmaceutical Services published news for 2020 q4
SEC form 6
2021-03-01 16:06 ET
West Pharmaceutical Services published news for 2020 q4
SEC form 10
2021-02-23 16:49 ET
West Pharmaceutical Services published news for 2020 q4
SEC form 6
2021-02-18 07:39 ET
West Pharmaceutical Services published news for 2020 q4
SEC form 6
2020-12-09 07:54 ET
West Pharmaceutical Services published news for 2020 q3
SEC form 6
2020-11-09 16:50 ET
West Pharmaceutical Services published news for 2020 q3
SEC form 6
2020-10-28 08:41 ET
West Pharmaceutical Services published news for 2020 q3
SEC form 10
2020-10-23 16:03 ET
West Pharmaceutical Services published news for 2020 q3
SEC form 6
2020-10-22 07:34 ET
West Pharmaceutical Services published news for 2020 q3